Michele Spina
YOU?
Author Swipe
View article: Enhanced Detection of αGal Using a Novel Monoclonal IgG1 Antibody: Comparative Evaluation with IgM Antibody [Clone M86]
Enhanced Detection of αGal Using a Novel Monoclonal IgG1 Antibody: Comparative Evaluation with IgM Antibody [Clone M86] Open
Introduction. Over the past two decades, the αGal (Galα1–3Galβ1–4GlcNAc–R) epitope, a carbohydrate found in many non-primate mammals, has gained significant relevance in medicine due to its association with an increasing number of allergic…
View article: Enhanced Detection of αGal Using a Novel Monoclonal IgG1 Antibody: Comparative Evaluation with IgM Antibody [clone M86]
Enhanced Detection of αGal Using a Novel Monoclonal IgG1 Antibody: Comparative Evaluation with IgM Antibody [clone M86] Open
Introduction. Over the past two decades, the αGal (Galα1–3Galβ1–4GlcNAc–R) epitope, a carbohydrate found in many non-primate mammals, has gained significant relevance in medicine due to its association with an increasing number of allergic…
View article: IUC24414-80 Optimizing sunitinib therapy in mRCC through pharmacological counseling and early TDM integration
IUC24414-80 Optimizing sunitinib therapy in mRCC through pharmacological counseling and early TDM integration Open
Background Sunitinib (SUN), a standard treatment for metastatic renal cell carcinoma (mRCC), demonstrates considerable interpatient variability in drug exposure and therapeutic response. Fixed dosing may lead to suboptimal drug levels, res…
View article: Multi-platform satellite-derived products during the 2025 Etna eruption
Multi-platform satellite-derived products during the 2025 Etna eruption Open
View article: Copanlisib in combination with rituximab and bendamustine for transplant‐ineligible relapsed/refractory diffuse large B‐cell lymphoma patients: Results from the phase <scp>II</scp> multicentre <scp>FIL</scp> Copa‐<scp>BR</scp> trial from Fondazione Italiana Linfomi (<scp>FIL</scp>)
Copanlisib in combination with rituximab and bendamustine for transplant‐ineligible relapsed/refractory diffuse large B‐cell lymphoma patients: Results from the phase <span>II</span> multicentre <span>FIL</span> Copa‐<span>BR</span> trial from Fondazione Italiana Linfomi (<span>FIL</span>) Open
Summary Treatment options for relapsed/refractory (R/R) diffuse large B‐cell lymphoma (DLBCL) patients ineligible for autologous stem cell transplant (ASCT) or chimeric antigen receptor (CAR)‐T‐cell therapy remain limited. The PI3K inhibit…
View article: 286 | THE SHORT‐TERM DOSE‐DENSE CARMEN PROGRAM IS ASSOCIATED WITH BETTER TOLERABILITY AND SIMILAR EFFICACY THAN OTHER INTENSIFIED REGIMENS IN HIGH‐GRADE B‐CELL LYMPHOMAS
286 | THE SHORT‐TERM DOSE‐DENSE CARMEN PROGRAM IS ASSOCIATED WITH BETTER TOLERABILITY AND SIMILAR EFFICACY THAN OTHER INTENSIFIED REGIMENS IN HIGH‐GRADE B‐CELL LYMPHOMAS Open
View article: 51 | LONG‐TERM BENEFIT AND MOLECULAR FEATURES OF PATIENTS WITH HCV‐ASSOCIATED INDOLENT LYMPHOMAS TREATED WITH DIRECT‐ACTING ANTIVIRALS: 6‐YEAR FOLLOW‐UP OF THE FIL_BArT STUDY
51 | LONG‐TERM BENEFIT AND MOLECULAR FEATURES OF PATIENTS WITH HCV‐ASSOCIATED INDOLENT LYMPHOMAS TREATED WITH DIRECT‐ACTING ANTIVIRALS: 6‐YEAR FOLLOW‐UP OF THE FIL_BArT STUDY Open
View article: 287 | SHORT‐TERM DOSE‐DENSE “CARMEN” THERAPY IS BETTER TOLERATED AND EVENLY EFFECTIVE THAN OTHER INTENSIFIED REGIMENS IN HIV‐ AND HIV+ PATIENTS WITH BURKITT LYMHOMA
287 | SHORT‐TERM DOSE‐DENSE “CARMEN” THERAPY IS BETTER TOLERATED AND EVENLY EFFECTIVE THAN OTHER INTENSIFIED REGIMENS IN HIV‐ AND HIV+ PATIENTS WITH BURKITT LYMHOMA Open
View article: 277 | PREPHASE TREATMENT WITH VITAMIN D SUPPLEMENTATION IN OLDER PATIENTS WITH DIFFUSE LARGE B‐CELL LYMPHOMA: A RANDOMIZED TRIAL BY FONDAZIONE ITALIANA LINFOMI
277 | PREPHASE TREATMENT WITH VITAMIN D SUPPLEMENTATION IN OLDER PATIENTS WITH DIFFUSE LARGE B‐CELL LYMPHOMA: A RANDOMIZED TRIAL BY FONDAZIONE ITALIANA LINFOMI Open
View article: Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor (EGFR) Common Mutations: New Strategies
Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor (EGFR) Common Mutations: New Strategies Open
Epidermal growth factor receptor (EGFR) mutations are described in 10–15% of Caucasian patients and in 50% of Asian patients with non-squamous non-small cell lung cancer (NSCLC). The introduction of tyrosine kinase inhibitors (TKIs) has re…
View article: 78P The integration of TDM and PGx in patients with mRCC receiving sunitinib treatment
78P The integration of TDM and PGx in patients with mRCC receiving sunitinib treatment Open
View article: Retrospective Analysis of R-COMP Therapy in Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Assessing the Impact of Sample Selection Bias
Retrospective Analysis of R-COMP Therapy in Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Assessing the Impact of Sample Selection Bias Open
Background: Retrospective studies are often criticized for their susceptibility to case selection bias compared to prospective studies, which include all patients consecutively and are thus less prone to such limitations. However, the larg…
View article: Immunotherapy in Oncogene-Addicted NSCLC: Evidence and Therapeutic Approaches
Immunotherapy in Oncogene-Addicted NSCLC: Evidence and Therapeutic Approaches Open
Non-small cell lung cancer (NSCLC) remains a leading cause of cancer-related mortality worldwide. The discovery of specific driver mutations has revolutionized the treatment landscape of oncogene-addicted NSCLC through targeted therapies, …
View article: Matters of the Heart: Cardiotoxicity Related to Target Therapy in Oncogene-Addicted Non-Small Cell Lung Cancer
Matters of the Heart: Cardiotoxicity Related to Target Therapy in Oncogene-Addicted Non-Small Cell Lung Cancer Open
The treatment of Non Small Cell Lung Cancer (NSCLC) has been revolutionised by the introduction of targeted therapies. With the improvement of response and frequently of overall survival, however, a whole new set of adverse events emerged.…
View article: EML4-ALK: Update on ALK Inhibitors
EML4-ALK: Update on ALK Inhibitors Open
Since the discovery of the first-generation ALK inhibitor, many other tyrosine kinase inhibitors have been demonstrated to be effective in the first line or further lines of treatment in patients with advanced non-small cell lung cancer wi…
View article: Navigating Therapeutic Challenges in BRAF-Mutated NSCLC: Non-V600 Mutations, Immunotherapy, and Overcoming Resistance
Navigating Therapeutic Challenges in BRAF-Mutated NSCLC: Non-V600 Mutations, Immunotherapy, and Overcoming Resistance Open
Although rare in non-small cell lung cancer (NSCLC), BRAF mutations present considerable therapeutic challenges. While the use of BRAF and MEK inhibitor combinations has significantly improved survival outcomes in patients with BRAF V600E …
View article: P198 Applying TDM and PGx in mRCC patients treated with Sunitinib to customize drug dosing
P198 Applying TDM and PGx in mRCC patients treated with Sunitinib to customize drug dosing Open
View article: Concordance between late effects reported by physicians and patients in a cohort of long-term Hodgkin lymphoma survivors: an analysis of data from nine consecutive EORTC-LYSA trials
Concordance between late effects reported by physicians and patients in a cohort of long-term Hodgkin lymphoma survivors: an analysis of data from nine consecutive EORTC-LYSA trials Open
Purpose Studies looking into the concordance between late effects reported by physicians vs. those reported by Hodgkin lymphoma (HL) survivors are missing. Methods A Life Situation Questionnaire focusing on late effects collected data from…
View article: 95P Implementation of TDM and PGx in mRCC patients treated with sunitinib to personalize drug dosing
95P Implementation of TDM and PGx in mRCC patients treated with sunitinib to personalize drug dosing Open
View article: Omission of Radiotherapy in Primary Mediastinal B-Cell Lymphoma: IELSG37 Trial Results
Omission of Radiotherapy in Primary Mediastinal B-Cell Lymphoma: IELSG37 Trial Results Open
PURPOSE The role of consolidation radiotherapy in patients with primary mediastinal B-cell lymphoma (PMBCL) is controversial. METHODS The IELSG37 trial, a randomized noninferiority study, aimed to assess whether irradiation can be omitted …
View article: Targeted Therapy in Mesotheliomas: Uphill All the Way
Targeted Therapy in Mesotheliomas: Uphill All the Way Open
Mesothelioma (MM) is an aggressive and lethal disease with few therapeutic opportunities. Platinum-pemetrexed chemotherapy is the backbone of first-line treatment for MM. The introduction of immunotherapy (IO) has been the only novelty of …
View article: Marginal zone lymphoma international prognostic index: a unifying prognostic index for marginal zone lymphomas requiring systemic treatment
Marginal zone lymphoma international prognostic index: a unifying prognostic index for marginal zone lymphomas requiring systemic treatment Open
View article: QUALITY OF CARE FOR PATIENTS WITH ACUTE MYOCARDIAL INFARCTION: RESULTS OF THE FIRST 3 MONTHS OF THE QUALITY IN CARDIOLOGY (QIC) PROJECT
QUALITY OF CARE FOR PATIENTS WITH ACUTE MYOCARDIAL INFARCTION: RESULTS OF THE FIRST 3 MONTHS OF THE QUALITY IN CARDIOLOGY (QIC) PROJECT Open
Background Assessing the quality of care is the first step for improve the management of patients with acute myocardial infarction (AMI). The European Society of Cardiology (ESC) and the Acute Cardiovascular Care Association (ACCA) recentl…
View article: Case report: First evidence of impressive efficacy of modulated dose selpercatinib in a young Caucasian with ANK3-RET fusion-positive NSCLC
Case report: First evidence of impressive efficacy of modulated dose selpercatinib in a young Caucasian with ANK3-RET fusion-positive NSCLC Open
Over the past decade, molecular characterization has led to change the management of advanced non-small cell lung cancer (NSCLC) harboring driver mutations. Rearranged during transfection ( RET ) gene fusions, occurring in 1% to 2% of NSCL…
View article: MYC rearrangements in HIV-associated large B-cell lymphomas: EUROMYC, a European retrospective study
MYC rearrangements in HIV-associated large B-cell lymphomas: EUROMYC, a European retrospective study Open
Large B-cell lymphoma (LBCL) carrying MYC rearrangement, alone or together with BCL2 and/or BCL6 translocations, have shown a poor prognosis when treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHO…
View article: The burden of rare variants in DPYS gene is a novel predictor of the risk of developing severe fluoropyrimidine-related toxicity
The burden of rare variants in DPYS gene is a novel predictor of the risk of developing severe fluoropyrimidine-related toxicity Open
Background Despite a growing number of publications highlighting the potential impact on the therapy outcome, rare genetic variants (minor allele frequency < 1%) in genes associated to drug adsorption, distribution, metabolism, and elimina…
View article: P1208: TRANSCRIPTOMIC PROFILING OF B CELL STATES AND MICROENVIROMENTAL ECOSYSTEMS REFINES THE PROGNOSTIC CLASSIFICATION OF DIFFUSE LARGE B CELL LYMPHOMA
P1208: TRANSCRIPTOMIC PROFILING OF B CELL STATES AND MICROENVIROMENTAL ECOSYSTEMS REFINES THE PROGNOSTIC CLASSIFICATION OF DIFFUSE LARGE B CELL LYMPHOMA Open
Topic: 20. Lymphoma Biology & Translational Research Background: Diffuse Large B-cell Lymphoma (DLBCL) is the most frequent aggressive lymphoma, originating either from the germinal-center (GCB) or post-germinal cells (ABC). Currently, res…
View article: S101: OMISSION OF RADIOTHERAPY IN PRIMARY MEDIASTINAL B-CELL LYMPHOMA PATIENTS FOLLOWING COMPLETE METABOLIC RESPONSE TO STANDARD IMMUNOCHEMOTHERAPY: RESULTS OF THE IELSG37 RANDOMISED TRIAL (NCT01599559)
S101: OMISSION OF RADIOTHERAPY IN PRIMARY MEDIASTINAL B-CELL LYMPHOMA PATIENTS FOLLOWING COMPLETE METABOLIC RESPONSE TO STANDARD IMMUNOCHEMOTHERAPY: RESULTS OF THE IELSG37 RANDOMISED TRIAL (NCT01599559) Open
Topic: 19. Aggressive Non-Hodgkin lymphoma - Clinical Background: Primary mediastinal B-cell lymphoma (PMBCL) has a good prognosis if remission is rapidly achieved with dose-intensive immunochemotherapy. In these patients, mediastinal radi…
View article: Therapeutical Options in ROS1—Rearranged Advanced Non Small Cell Lung Cancer
Therapeutical Options in ROS1—Rearranged Advanced Non Small Cell Lung Cancer Open
ROS proto-oncogene 1 (ROS1) rearrangements occur in 0.9–2.6% of patients with non small cell lung cancer (NSCLC), conferring sensitivity to treatment with specific tyrosine-kinase inhibitors (TKI). Crizotinib, a first-generation TKI, was t…
View article: Liquid Biopsy in NSCLC: An Investigation with Multiple Clinical Implications
Liquid Biopsy in NSCLC: An Investigation with Multiple Clinical Implications Open
Tissue biopsy is essential for NSCLC diagnosis and treatment management. Over the past decades, liquid biopsy has proven to be a powerful tool in clinical oncology, isolating tumor-derived entities from the blood. Liquid biopsy permits sev…